Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko Chief to Take 50% Pay Cuts until Business Recovery
May 20, 2021
- 5-Camp Battle Heating Up in HIF-PH Market; Evrenzo, Duvroq Neck-and-Neck for Top Spot
May 19, 2021
- Fujifilm, BlueRock Form Strategic Alliance to Develop iPSC Therapies for Ocular Diseases
May 19, 2021
- Tord Labuda Becomes Interim Chief of LEO Pharma Japan, Sakurai Resigns
May 19, 2021
- Reps’ Face-to-Face Meetings for GPs Back to Prepandemic Levels in March: Intage
May 19, 2021
- Nichi-Iko Refrains from June Listing to Focus on Re-Supply of Existing Drugs
May 18, 2021
- Nipro Pharma to Build New Injectable Plant in Shiga
May 18, 2021
- Takeda, Fujitsu, NCC Join Forces to Analyze Journey of Ovarian Cancer Patients
May 18, 2021
- Big 4 Wholesalers’ Operating Margin Sinks to 0.49% on COVID-19, Competition
May 17, 2021
- 2 Ono Employees Admits Bribery Charges over Onoact Prescriptions
May 17, 2021
- Eisai, NCC Strike Drug Discovery Deal on Rare/Refractory Cancers
May 17, 2021
- Astellas/Seagen’s ADC Enfortumab Vedotin Gets Priority Review in Japan
May 17, 2021
- Astellas, Kyoto University VC Pair Up on Cross-Disciplinary Drug Discovery
May 17, 2021
- FY2020 Sales of 7 Major Japan Drug Makers Slip 2.7% on COVID-19, Price Woes: Tally
May 14, 2021
- Japan Ethical Drug Sales Up 5.7% in March: Crecon
May 14, 2021
- Opdivo Top-Selling Drug in Japan in April: Encise
May 14, 2021
- Otsuka’s Q1 Pharma Sales Down 5.0% on Japan Dip, 4 Global Brands Grow
May 14, 2021
- Daiichi Sankyo Seeks Central Neuropathic Pain Use for Tarlige
May 14, 2021
- Ono Cuts Opdivo Guidance to 110 Billion Yen for FY2021
May 14, 2021
- Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims for Antibody Cocktail Filing in 2021: President
May 14, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…